Latest Breaking News On - வார்டன் பள்ளி ஆஃப் வணிக - Page 7 : comparemela.com

  SANTA CLARA, Calif., July 21, 2021 /PRNewswire/ Axon Therapies, a private company focused on addressing a root cause of heart failure, today announced the appointment of seasoned medical device executive Chad Hoskins as Chief Executive Officr (CEO). Mr. Hoskins will lead the company as it transitions from early development towards regulatory clearance and commercialization of its novel heart failure treatment, splanchnic ablation for volume management (SAVM), using the Satera™ Ablation System. Axon is poised to disrupt the heart failure market by treating a root cause of the disease rather than simply addressing patient symptoms.  We are very pleased with our initial data demonstrating the potential of SAVM to improve the quality of life of heart failure patients with preserved ejection fraction, commented Howard Levin, MD, Co-founder of Axon Therapies and Deerfield Catalyst, a medtech innovation hub. Chad s deep understanding of the heart failure market and proven leade

United statesHoward levinHeart failure society of americaColumbia universityPublic healthWharton school of businessGeorgetown universityDivision viceUniversity of pennsylvaniaMckinsey companyBusiness administrationAxon therapies incChad hoskinsChief executive officrAxon therapiesDeerfield catalyst